Corrigendum to “Beta cell specific cannabinoid 1 receptor deletion counteracts progression to hyperglycemia in non-obese diabetic mice” [Mol Metab 82 (2024 April) 101906]

• Kanikkai Raja Aseer,
• Caio Henrique Mazucanti,
• Jennifer F. O’Connell,
• Isabel González-Mariscal,
• Anjali Verma,
• Qin Yao,
• Christopher Dunn,
• Qing-Rong Liu,
• Josephine M. Egan,
• Máire E. Doyle

Affiliations

Kanikkai Raja Aseer

Laboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA; Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA

Caio Henrique Mazucanti

Laboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA

Jennifer F. O’Connell

Laboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA

Isabel González-Mariscal

Inserm UMR1190 - Translational Research of Diabetes, Pôle recherche 3ème Ouest, 1, place de Verdun 59045 Lille Cedex, France

Anjali Verma

Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA

Qin Yao

Laboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA

Christopher Dunn

Laboratory of Molecular Biology & Immunology, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA

Qing-Rong Liu

Laboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA

Josephine M. Egan

Laboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA

Máire E. Doyle

Laboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA; Corresponding author. Laboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.